BioStock: Positive results from Aptahem’s collaboration with Örebro University
At the end of last year, Aptahem entered a consortium with Örebro University with the aim to evaluate new strategies to reduce inflammation, thrombosis and fibrosis in cardiovascular disease. Yesterday, the company was able to announce the first preliminary data from the project and these confirmed the anti-inflammatory and non-toxic properties of Aptahem’s drug candidate Apta-1. In addition, the data also indicated that the candidate may have a positive effect on inflammation in blood vessels.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se